Literature DB >> 34741716

Lipid metabolism reprogramming in renal cell carcinoma.

Gioia Heravi1, Omid Yazdanpanah2, Izabela Podgorski3,4,5, Larry H Matherly3,4,5, Wanqing Liu6,7,8,9.   

Abstract

Metabolic reprogramming is recognized as a hallmark of cancer. Lipids are the essential biomolecules required for membrane biosynthesis, energy storage, and cell signaling. Altered lipid metabolism allows tumor cells to survive in the nutrient-deprived environment. However, lipid metabolism remodeling in renal cell carcinoma (RCC) has not received the same attention as in other cancers. RCC, the most common type of kidney cancer, is associated with almost 15,000 death in the USA annually. Being refractory to conventional chemotherapy agents and limited available targeted therapy options has made the treatment of metastatic RCC very challenging. In this article, we review recent findings that support the importance of synthesis and metabolism of cholesterol, free fatty acids (FFAs), and polyunsaturated fatty acids (PUFAs) in the carcinogenesis and biology of RCC. Delineating the detailed mechanisms underlying lipid reprogramming can help to better understand the pathophysiology of RCC and to design novel therapeutic strategies targeting this malignancy.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cholesterol; Free fatty acids; Metabolic reprogramming; PUFA; Renal cell carcinoma

Mesh:

Substances:

Year:  2021        PMID: 34741716     DOI: 10.1007/s10555-021-09996-w

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  100 in total

1.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors:  Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

Review 2.  Renal cell carcinoma.

Authors:  James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra
Journal:  Nat Rev Dis Primers       Date:  2017-03-09       Impact factor: 52.329

3.  Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.

Authors:  Thomas Powles; Elizabeth R Plimack; Denis Soulières; Tom Waddell; Viktor Stus; Rustem Gafanov; Dmitry Nosov; Frédéric Pouliot; Bohuslav Melichar; Ihor Vynnychenko; Sergio J Azevedo; Delphine Borchiellini; Raymond S McDermott; Jens Bedke; Satoshi Tamada; Lina Yin; Mei Chen; L Rhoda Molife; Michael B Atkins; Brian I Rini
Journal:  Lancet Oncol       Date:  2020-10-23       Impact factor: 41.316

4.  Surveillance strategies for renal cell carcinoma patients following nephrectomy.

Authors:  Arnold I Chin; John S Lam; Robert A Figlin; Arie S Belldegrun
Journal:  Rev Urol       Date:  2006

Review 5.  Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer.

Authors:  Marteinn Thor Snaebjornsson; Sudha Janaki-Raman; Almut Schulze
Journal:  Cell Metab       Date:  2019-12-05       Impact factor: 27.287

Review 6.  The role of cholesterol metabolism in cancer.

Authors:  Xiao Ding; Weihua Zhang; Song Li; Hui Yang
Journal:  Am J Cancer Res       Date:  2019-02-01       Impact factor: 6.166

7.  Body size and renal cell cancer incidence in a large US cohort study.

Authors:  Kenneth F Adams; Michael F Leitzmann; Demetrius Albanes; Victor Kipnis; Steven C Moore; Arthur Schatzkin; Wong-Ho Chow
Journal:  Am J Epidemiol       Date:  2008-06-09       Impact factor: 4.897

Review 8.  Metabolomics and Metabolic Reprogramming in Kidney Cancer.

Authors:  Robert H Weiss
Journal:  Semin Nephrol       Date:  2018-03       Impact factor: 5.299

9.  Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Authors:  Tobias Pischon; Petra H Lahmann; Heiner Boeing; Anne Tjønneland; Jytte Halkjaer; Kim Overvad; Kerstin Klipstein-Grobusch; Jakob Linseisen; Nikolaus Becker; Antonia Trichopoulou; Vassiliki Benetou; Dimitrios Trichopoulos; Sabina Sieri; Domenico Palli; Rosario Tumino; Paolo Vineis; Salvatore Panico; Evelyn Monninkhof; Petra H M Peeters; H Bas Bueno-de-Mesquita; Frederike L Büchner; Börje Ljungberg; Göran Hallmans; Göran Berglund; Carlos Alberto Gonzalez; Miren Dorronsoro; Aurelio Barricarte Gurrea; Carmen Navarro; Carmen Martinez; J Ramón Quirós; Andrew Roddam; Naomi Allen; Sheila Bingham; Kay-Tee Khaw; Rudolf Kaaks; Teresa Norat; Nadia Slimani; Elio Riboli
Journal:  Int J Cancer       Date:  2006-02-01       Impact factor: 7.396

10.  Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

Authors:  Laurence Albiges; Nizar M Tannir; Mauricio Burotto; David McDermott; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Thomas Powles; Frede Donskov; Saby George; Christian K Kollmannsberger; Howard Gurney; Marc-Oliver Grimm; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Toni K Choueiri; Shruti Shally Saggi; M Brent McHenry; Robert J Motzer
Journal:  ESMO Open       Date:  2020-11
View more
  4 in total

1.  Serum Eicosanoids Metabolomics Profile in a Mouse Model of Renal Cell Carcinoma: Predicting the Antitumor Efficacy of Anlotinib.

Authors:  Ping Du; Lingling Xuan; Ting Hu; Zhuoling An; Lihong Liu
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

2.  Decrease of Intracellular Glutamine by STF-62247 Results in the Accumulation of Lipid Droplets in von Hippel-Lindau Deficient Cells.

Authors:  Mathieu Johnson; Sarah Nowlan; Gülsüm Sahin; David A Barnett; Andrew P Joy; Mohamed Touaibia; Miroslava Cuperlovic-Culf; Daina Zofija Avizonis; Sandra Turcotte
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

3.  Fatty acid desaturase 1 (FADS1) is a cancer marker for patient survival and a potential novel target for precision cancer treatment.

Authors:  Gioia Heravi; Hyejeong Jang; Xiaokun Wang; Ze Long; Zheyun Peng; Seongho Kim; Wanqing Liu
Journal:  Front Oncol       Date:  2022-08-15       Impact factor: 5.738

4.  Dual-tracer positron emission tomography/computed tomography as an imaging probe of de novo lipogenesis in preclinical models of hepatocellular carcinoma.

Authors:  Chin-Ho Tsao; Rong-Hong Jhou; Chien-Chih Ke; Chun-Wei Chang; Chi-Wei Chang; Bang-Hung Yang; Wen-Sheng Huang; Bing-Fu Shih; Ren-Shyan Liu
Journal:  Front Med (Lausanne)       Date:  2022-09-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.